Top

Cancer Chemotherapy and Pharmacology

Published in:

Open Access 01-03-2011 | Original Article

Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists

Authors: N. Percie du Sert, J. A. Rudd, C. C. Apfel, P. L. R. Andrews

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2011

Abstract

Purpose

The ferret cisplatin emesis model has been used for ~30 years and enabled identification of clinically used anti-emetics. We provide an objective assessment of this model including efficacy of 5-HT₃ receptor antagonists to assess its translational validity.

Methods

A systematic review identified available evidence and was used to perform meta-analyses.

Results

Of 182 potentially relevant publications, 115 reported cisplatin-induced emesis in ferrets and 68 were included in the analysis. The majority (n = 53) used a 10 mg kg⁻¹ dose to induce acute emesis, which peaked after 2 h. More recent studies (n = 11) also used 5 mg kg⁻¹, which induced a biphasic response peaking at 12 h and 48 h. Overall, 5-HT₃ receptor antagonists reduced cisplatin (5 mg kg⁻¹) emesis by 68% (45–91%) during the acute phase (day 1) and by 67% (48–86%) and 53% (38–68%, all P < 0.001), during the delayed phase (days 2, 3). In an analysis focused on the acute phase, the efficacy of ondansetron was dependent on the dosage and observation period but not on the dose of cisplatin.

Conclusion

Our analysis enabled novel findings to be extracted from the literature including factors which may impact on the applicability of preclinical results to humans. It reveals that the efficacy of ondansetron is similar against low and high doses of cisplatin. Additionally, we showed that 5-HT₃ receptor antagonists have a similar efficacy during acute and delayed emesis, which provides a novel insight into the pharmacology of delayed emesis in the ferret.

Altman DG (1991) Practical statistics for medical research. Chapman & Hall, London

Andrews PLR, Horn CC (2006) Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 125:100–115PubMedCrossRef

Andrews PLR, Rudd JA (2004) The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Holzer P (ed) Handbook of experimental pharmacology. Springer, Berlin

Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (1993) Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol 232:139–145PubMedCrossRef

Barnes JM, Barnes NM, Costall B, Naylor RJ, Tattersall FD (1988) Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret. Neuropharmacology 27:783–790PubMedCrossRef

Barnes NM, Barry JM, Costall B, Naylor RJ, Tattersall FD (1987) Antagonism by para-chlorophenylalanine of cisplatin-induced emesis. Br J Pharmacol 92:649P

Barnes NM, Bunce KT, Naylor RJ, Rudd JA (1991) The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 30:1073–1083PubMedCrossRef

Bebarta V, Luyten D, Heard K (2003) Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med 10:684–687PubMed

Bermudez J, Boyle EA, Miner WD, Sanger GJ (1988) The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 58:644–650PubMedCrossRef

10.

Bhandari P, Gupta YK, Seth SD, Chugh A (1988) Emetic profile of cisplatin in dogs. Asia Pac J Pharmacol 3:131–133

11.

Bingham S, Blower PR, Davey PT, King PD, Sanger GJ, Wardle KA, Nishioka Y (1994) Differences between the anti-emetic efficacies of the 5-HT3 receptor antagonists Granisetron and Azasetron in the conscious ferret. Pharmacometrics 47:21–28

12.

Blower PR (1990) The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 26(Suppl 1):S8–S11PubMed

13.

Blum E, Buchheit KH, Buecher HH, Gamse R, Kloeppner E, Meigel H, Papageorgiou C, Waelchli R, Revesz L (1992) Design and synthesis of novel ligands for the 5-HT4 and the 5-HT4 receptor. Bioorg Med Chem Lett 2:461–466CrossRef

14.

Borison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5:193–230PubMed

15.

Bountra C, Bunce K, Dale T, Gardner C, Jordan C, Twissell D, Ward P (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99, 994, in ferrets. Eur J Pharmacol 249:R3–R4PubMedCrossRef

16.

Chevalier E, Singh L, Diop L (1998) Anti-emetic effects of PD154075. Gastroenterology 114:A578CrossRef

17.

Clark RD, Miller AB, Berger J, Repke DB, Weinhardt KK, Kowalczyk BA, Eglen RM, Bonhaus DW, Lee CH, Michel AD et al (1993) 2-(Quinuclidin-3-yl)pyrido[4, 3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. J Med Chem 36:2645–2657PubMedCrossRef

18.

Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, Owera-Atepo JB, Simpson KM, Tan CC, Tattersall D (1987) The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology 26:669–677PubMedCrossRef

19.

Costall B, Domeney AM, Gunning SJ, Naylor RJ, Tattersall D, Tyers MB (1987) GR38032F: a potent and novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol 90:90P

20.

Costall B, Domeney AM, Naylor RJ, Owera-Atepo JB, Rudd JA, Tattersall FD (1990) Fluphenazine, ICS 205–930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 29:453–462PubMedCrossRef

21.

Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25:959–961PubMedCrossRef

22.

Costall B, Domeney AM, Naylor RJ, Tattersall FD (1987) Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology 26:1321–1326PubMedCrossRef

23.

Costall B, Naylor RJ, Tattersall FD (1990) The actions of fenfluramine and interaction with 5-HT3 receptor-antagonists to inhibit emesis in the ferret. J Pharm Pharmacol 42:94–101PubMed

24.

Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810–816PubMedCrossRef

25.

Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777–794PubMedCrossRef

26.

Davis CJ (1988) Neuropharmacological investigations into the mechanisms of emesis caused by cytotoxic drugs and radiation. Clinical pharmacology. Oxford University, PhD thesis

27.

Delagrange P, Emerit MB, Merahi N, Abraham C, Morain P, Rault S, Renard P, Pfeiffer B, Guardiola-Lemaitre B, Hamon M (1996) Interaction of S 21007 with 5-HT3 receptors. In vitro and in vivo characterization. Eur J Pharmacol 316:195–203PubMedCrossRef

28.

DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114PubMedCrossRef

29.

Eglen RM, Bonhaus DW, Clark RD, Johnson LG, Lee CH, Leung E, Smith WL, Wong EH, Whiting RL (1994) (R) and (S) RS 56532: mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity. Neuropharmacology 33:515–526PubMedCrossRef

30.

Eglen RM, Lee CH, Smith WL, Johnson LG, Clark R, Whiting RL, Hegde SS (1995) Pharmacological characterization of RS 25259–197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 114:860–866PubMed

31.

Eglen RM, Lee CH, Smith WL, Johnson LG, Whiting RL, Hegde SS (1993) RS 42358–197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 266:535–543PubMed

32.

Endo T, Minami M, Monma Y, Saito H, Takeuchi M (1990) Emesis-related biochemical and histopathological changes induced by cisplatin in the ferret. J Toxicol Sci 15:235–244PubMed

33.

Endo T, Minami M, Monma Y, Yoshioka M, Saito H, Kinami J, Toshimitsu Y, Parvez SH (1990) Effect of GR38032F on cisplatin- and cyclophosphamide-induced emesis in the ferret. Biog Amines 7:525–533

34.

Endo T, Minami M, Monma Y, Yoshioka M, Saito H, Parvez SH (1992) Vagotomy and ondansetron (5-HT3 antagonist) inhibited the increase of serotonin concentration induced by cytotoxic drugs in the area postreama of ferrets. Biog amines 9:163–175

35.

Endo T, Nemoto M, Minami M, Yoshioka M, Saito H, Parvez SH (1995) Changes in the afferent abdominal vagal nerve activity induced by cisplatin and copper sulfate in the ferret. Biog Amines 11:399–407

36.

Endo T, Nemoto M, Monma Y, Hamaue N, Togashi M, Hirafuji M (1994) Combined effect of domperidone and granisetron on cisplatin-induced emesis in the ferret. Pharmacometrics 47:435–442

37.

European Medicines Agency (2006) Guideline on non-clinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy. CPMP/EWP/4937/03. In: EMEA (ed) London, UK

38.

Fink-Jensen A, Judge ME, Hansen JB, Jacobsen P, Turski L, Olney J, Honore T (1992) Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX. Neurosci Lett 137:173–177PubMedCrossRef

39.

Fitzpatrick LR, Lambert RM, Pendley CE, Martin GE, Bostwick JS, Gessner GW, Airey JE, Youssefyeh RD, Pendleton RG, Decktor DL (1990) RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog. J Pharmacol Exp Ther 254:450–455PubMed

40.

Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatin-induced emesis in the Ferret: a new animal model. Cancer Treat Rep 66:187–189PubMed

41.

Florczyk AP, Schurig JE, Lenaz L, Bradner WT (1981) the ferret: a new animal model of cis-platinum induced emesis. Proc Am Assoc Canc Res 22:228

42.

Fukunaka N, Sagae S, Kudo R, Endo T, Hirafuji M, Minami M (1998) Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Gen Pharmacol 31:775–781PubMed

43.

Gandara, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 29A(Suppl 1):S35–S38PubMedCrossRef

44.

Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P (1996) GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65:45–53PubMedCrossRef

45.

Gardner CJ, Bountra C, Bunce KT, Dale TJ, Jordan CC, Twissell DJ, Ward P (1994) Anti-emetic activity of neurokinin NK1 receptor antagonists is mediated centrally. Br J Pharmacol 112:516P

46.

Gardner CJ, Twissell DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P (1995) The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 116:3158–3163PubMed

47.

Gonsalves S, Watson J, Ashton C (1996) Broad spectrum antiemetic effects of CP-122, 721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305:181–185PubMedCrossRef

48.

Gooch CL, Boissonade FM, Grundy D (1998) Somatostatin analogue octreotide inhibits retching to cisplatin in anaesthetised ferret. Gastroenterology 114:A1147CrossRef

49.

Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR (1988) BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther 244:830–837PubMed

50.

Haga K, Inaba K, Shoji H, Morimoto Y, Fukuda T, Setoguchi M (1993) The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn J Pharmacol 63:377–383PubMedCrossRef

51.

Haga K, Inaba K, Syoji H (2000) The effect of azasetron hydrochloride (serotone (TM)) on delayed emesis induced by a chemotherapeutic agent, cisplatin. Jpn Pharmacol Ther 28:285–290

52.

Hale JJ, Mills SG, MacCoss M, Dorn CP, Finke PE, Budhu RJ, Reamer RA, Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH, Cascieri MA, Chicchi GG, Kurtz MM, Sadowski S, Ber E, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, Metzger JM, MacIntyre DE (2000) Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 43:1234–1241PubMedCrossRef

53.

Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J, Eiermann G, Tsou NN, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, MacIntyre DE (1998) Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1, 2, 4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 41:4607–4614PubMedCrossRef

54.

Hargreaves R, Tattersall D, Rycroft W, Woodford K, Ladduwahetty T, Keown L, Merchant K, Swain C, MacLeod AM, Baker R, Francis B, Burns D, Cascieri M, Metzger J, MacIntyre DE, Williamson DJ, Iversen LL, Hill RG (1994) Evidence that the anti-emetic effects of NK1 receptor antagonists are centrally mediated. Can J Physiol Pharmacol 72(suppl 2):45

55.

Harris AL, Cantwell BMJ (1986) Mechanisms and treatment of cytotoxic-induced nausea and vomiting. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG (eds) Nausea and vomiting: mechanisms and treatment. Springer, Berlin, pp 78–93

56.

Hawthorn J, Ostler KJ, Andrews PLR (1988) The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol 73:7–21PubMed

57.

Hesketh PJ (2005) Management of nausea and vomiting in cancer and cancer treatment. Jones and Barlett Publishers Inc., Sudbury

58.

Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989) GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705PubMed

59.

Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB (1989) 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247–255PubMed

60.

Hollingworth GJ, Carlson EJ, Castro JL, Chicchi GG, Clark N, Cooper LC, Dirat O, Salvo JD, Elliott JM, Kilburn R, Kurtz MM, Rycroft W, Tattersall FD, Tsao KL, Swain CJ (2006) Novel lactam NK1 antagonists with anti-emetic activity. Bioorg Med Chem Lett 16:1197–1201PubMedCrossRef

61.

Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR (2009) Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 157:865–880PubMedCrossRef

62.

Horn J, de Haan RJ, Vermeulen M, Luiten PG, Limburg M (2001) Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 32:2433–2438PubMedCrossRef

63.

Horn J, Limburg M (2001) Calcium antagonists for ischemic stroke: a systematic review. Stroke 32:570–576PubMedCrossRef

64.

Ito T, Yoshida N, Miura Y, Omoya H, Karasawa T (1990) Antiemetic effects of AS-5370, a novel serotonin 5-HT3 receptor antagonist. Eur J Pharmacol 183:1214–1215CrossRef

65.

Jantunen IT, Kataja VV, Muhonen TT (1997) An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66–74PubMedCrossRef

66.

Kamato T, Ito H, Nagakura Y, Nishida A, Yuki H, Yamano M, Miyata K (1993) Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets. Eur J Pharmacol 238:369–376PubMedCrossRef

67.

Kamato T, Miyata K, Ito H, Yuki H, Yamano M, Honda K (1991) Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs. Jpn J Pharmacol 57:387–395PubMedCrossRef

68.

Kilkenny C (2008) Systematic reviews of animal research. Available online at: http://www.nc3rs.org.uk/downloaddoc.asp?id=695

69.

Kim JH, Yoon IS, Lee BH, Choi SH, Lee JH, Lee JH, Jeong SM, Kim SC, Park CK, Lee SM, Nah SY (2005) Effects of Korean red ginseng extract on cisplatin-induced nausea and vomiting. Arch Pharm Res 28:680–684PubMedCrossRef

70.

King AG, Sanger GJ (2005) Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret. Neurosci Lett 376:5–8PubMedCrossRef

71.

Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD (1996) Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78:2193–2198PubMedCrossRef

72.

Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384PubMed

73.

Kubota Y, Mihara K, Ishii F, Ohno K, Ogata H, Makimura M, Kikuchi N, Kitano T (2004) Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review. Yakugaku Zasshi 124:1–11PubMedCrossRef

74.

Lasheras B, Berjon A, Montanes R, Roca J, Romero G, Ramirez MJ, Del Rio J (1996) Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists. Arzneimittelforschung 46:401–406PubMed

75.

Lau AH, Kan KK, Lai HW, Ngan MP, Rudd JA, Wai MK, Yew DT (2005) Action of ondansetron and CP-99, 994 to modify behavior and antagonize cisplatin-induced emesis in the ferret. Eur J Pharmacol 506:241–247PubMedCrossRef

76.

Lehmann A, Karrberg L (1996) Effects of N-methyl-D-aspartate receptor antagonists on cisplatin-induced emesis in the ferret. Neuropharmacology 35:475–481PubMedCrossRef

77.

Liu YL, Malik NM, Sanger GJ, Andrews PL (2006) Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 58:326–333PubMedCrossRef

78.

Macleod MR, O’Collins T, Horky LL, Howells DW, Donnan GA (2005) Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 38:35–41PubMedCrossRef

79.

Macleod MR, O’Collins T, Horky LL, Howells DW, Donnan GA (2005) Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25:713–721PubMedCrossRef

80.

Macleod MR, O’Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35:1203–1208PubMedCrossRef

81.

Marr HE, Davey PT, Blower PR (1992) The effect of dexamethasone, alone or in combination with granisetron, on cisplatin-induced emesis in the ferret. Br J Pharmacol 104:371P

82.

Marr HE, Davey PT, Boyle EA, Blower PR (1994) Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology 48:283–292PubMedCrossRef

83.

Marr HE, Davey PT, Boyle EA, Blower PR (1994) The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets. J Cancer Res Clin Oncol 120:204–207PubMedCrossRef

84.

Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26–31PubMedCrossRef

85.

Marty M, Kleisbauer JP, Fournel P, Vergnenegre A, Carles P, Loria-Kanza Y, Simonetta C, de Bruijn KM (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group. Anticancer Drugs 6(Suppl 1):15–21PubMedCrossRef

86.

Matsui T, Sugiura T, Nakai H, Iguchi S, Shigeoka S, Takada H, Odagaki Y, Nagao Y, Ushio Y, Ohmoto K et al (1992) Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones. J Med Chem 35:3307–3319PubMedCrossRef

87.

Matthews JN, Altman DG (1996) Interaction 3: How to examine heterogeneity. BMJ 313:862PubMed

88.

Matthews RA (2008) Medical progress depends on animal models—doesn’t it? J R Soc Med 101:95–98PubMedCrossRef

89.

McCarthy LE, Borison HL (1974) Respiratory mechanics of vomiting in decerebrate cats. Am J Physiol 226:738–743PubMed

90.

Miller RC, Galvan M, Gittos MW, Van Giersbergen PLM, Moser PC, Fozard JR (1993) Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 28:87–93CrossRef

91.

Minami M, Endo T, Kikuchi K, Ihira E, Hirafuji M, Hamaue N, Monma Y, Sakurada T, Tan-no K, Kisara K (1998) Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret. Eur J Pharmacol 363:49–55PubMedCrossRef

92.

Minami M, Endo T, Monma Y, Shiroshita Y (1991) Pharmacoogy of emesis induced by anti cancer drugs. J Toxicol Sci 16(suppl 2):35–39

93.

Minami M, Endo T, Tamakai H, Ogawa T, Hamaue N, Hirafuji M, Monma Y, Yoshioka M, Hagihara K (1997) Antiemetic effects of N-3389, a newly synthesized 5-HT3 and 5-HT4 receptor antagonist, in ferrets. Eur J Pharmacol 321:333–342PubMedCrossRef

94.

Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497–499PubMed

95.

Miner WD, Sanger GJ, Turner DH (1986) Comparison of the effect of BRL 24924, metoclopramide and domperidone on cisplatin-induced emesis in the ferret. Br J Pharmacol 88:374P

96.

Miner WD, Sanger GJ, Turner DH (1987) Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 56:159–162PubMedCrossRef

97.

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRef

98.

Monkovic I, Willner D, Adam MA, Brown M, Crenshaw RR, Fuller CE, Juby PF, Luke GM, Matiskella JA, Montzka TA (1988) Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis. J Med Chem 31:1548–1558PubMedCrossRef

99.

Nakayama H, Yamakuni H, Higaki M, Ishikawa H, Imazumi K, Matsuo M, Mutoh S (2005) Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci 98:396–403PubMedCrossRef

100.

Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC et al (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408–2416PubMed

101.

Nuffield Council on Bioethics (2005) The ethics of research involving animals. In: Bioethics NCo (ed) London

102.

Ohta M, Suzuki T, Furuya T, Kurihara H, Tokunaga T, Miyata K, Yanagisawa I (1996) Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives. Chem Pharm Bull (Tokyo) 44:1707–1716

103.

Ozaki A, Sukamoto T (1999) Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist. Gen Pharmacol 33:283–288PubMedCrossRef

104.

Percie du Sert N, Rudd JA, Moss R, Andrews PLR (2009) The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. Neurosci Lett 465:16–20PubMedCrossRef

105.

Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I (2004) Where is the evidence that animal research benefits humans? BMJ 328:514–517PubMedCrossRef

106.

Preziosi P, D’Amato M, Del Carmine R, Martire M, Pozzoli G, Navarra P (1992) The effects of 5-HT3 receptor antagonists on cisplatin-induced emesis in the pigeon. Eur J Pharmacol 221:343–350PubMedCrossRef

107.

Price MT, Olney JE (1990) Excitatory amino acid antagonists as anti-emetics. Soc Neurosci Abstr 16:377

108.

Reynolds DJ, Barber NA, Grahame-Smith DG, Leslie RA (1991) Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res 565:231–236PubMedCrossRef

109.

Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28PubMedCrossRef

110.

Rudd JA, Andrews PLR (2005) Mechanisms of acute and delayed Nausea and vomiting induced by anticancer therapies. In: Hesketh P (ed) Management of Nausea and vomiting in cancer and cancer treatment. Jones and Barlett Publishers, Inc., Sudbury, pp 15–66

111.

Rudd JA, Bunce KT, Naylor RJ (1992) The effect of 8-OH-DPAT on drug-induced emesis in the ferret. Br J Pharmacol 106:101P

112.

Rudd JA, Bunce KT, Naylor RJ (1996) The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology 35:91–97PubMedCrossRef

113.

Rudd JA, Cheng CH, Naylor RJ (1998) Serotonin-independent model of cisplatin-induced emesis in the ferret. Jpn J Pharmacol 78:253–260PubMedCrossRef

114.

Rudd JA, Jordan CC, Naylor RJ (1994) Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur J Pharmacol 262:R1–R2PubMedCrossRef

115.

Rudd JA, Jordan CC, Naylor RJ (1996) The action of the NK1 tachykinin receptor antagonist, CP 99, 994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119:931–936PubMed

116.

Rudd JA, Kan KW, Ngan MP, Okuno T, Sam TS (2001) Anti-emetic action of intranasally administered metoclopramide in the ferret. Presented at: 7th Hong Kong Pharmacology Society Scientific meeting in Association with the Zhjiang Pharmacological Society, Hong Kong, China, 16–18 October

117.

Rudd JA, Naylor RJ (1994) Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33:1607–1608PubMedCrossRef

118.

Rudd JA, Naylor RJ (1994) Modulation of emesis by 5HT1A receptors. Pathophysiology 1:267–268CrossRef

119.

Rudd JA, Naylor RJ (1996) An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118:209–214PubMed

120.

Rudd JA, Naylor RJ (1997) The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret. Eur J Pharmacol 322:79–82PubMedCrossRef

121.

Rudd JA, Ngan MP, Wai MK (1998) 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur J Pharmacol 352:143–149PubMedCrossRef

122.

Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PLR, Sanger GJ (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392:79–83PubMedCrossRef

123.

Rudd JA, Sam TS, Ngan MP (2006) A COX and LOX inhibitor regimen fails to mimic the action of dexamethasone on cisplatin-induced acute and delayed emesis in the Ferret. IUPHAR-2006, Beijing

124.

Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 51:113–118PubMedCrossRef

125.

Rupniak NM, Tattersall FD, Williams AR, Rycroft W, Carlson EJ, Cascieri MA, Sadowski S, Ber E, Hale JJ, Mills SG, MacCoss M, Seward E, Huscroft I, Owen S, Swain CJ, Hill RG, Hargreaves RJ (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol 326:201–209PubMedCrossRef

126.

Russell WM, Burch RL (1959) The principles of humane experimental technique. Universities Federation For Animal Welfare (UFAW)

127.

Rycroft W, Tattersall D, Ber E, Cascieri M, Hale JJ, Hill RG, MacCoss M, Mills SG, Sadowski S, Hargreaves R (1996) The anti-emetic actions of L-742,694, poster

128.

Sam TS, Chan SW, Rudd JA, Yeung JH (2001) Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 417:231–237PubMedCrossRef

129.

Sam TS, Kan KK, Ngan MP, Rudd JA, Yeung JH (2003) Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 466:163–168PubMedCrossRef

130.

Sam TS, Ngan MP, Riendeau D, Robichaud A, Rudd JA (2007) Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret. J Pharmacol Sci 103:189–200PubMedCrossRef

131.

Schurig JE, Florczyk AP, Rose WC, Bradner WT (1982) Antiemetic activity of butorphanol against cisplatin-induced emesis in ferrets and dogs. Cancer Treat Rep 66:1831–1835PubMed

132.

Shiroshita Y, Minami M, Endo T, Monma Y, Asaka M, Itoh H, Ikeda T, Matsumoto H, Satoh T (1993) The protective effect of 4-hydroxy-2-methyl-N-[2-(tetrazol-5-yl)- phenyl]-2H–1, 2-benzothiazine-3-carboxamide-1, 1-dioxide monosodium salt (HX-1920) on cisplatin-induced toxicity in rats. J Toxicol Sci 18:31–41PubMed

133.

Shiroshita Y, Minami M, Endo T, Takahashi M, Monma Y, Hiromishi I, Yokoyama R, Matsumoto K (1992) Effects of HX-1920 on cisplatin-induced toxicity in mice, rat and ferrets. Jpn J Pharmacol 58:419P

134.

Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, Wright DS, Naylor RJ (1997) The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur J Pharmacol 321:209–216PubMedCrossRef

135.

Spina D (2004) The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 3:231–236PubMedCrossRef

136.

Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylor RJ, Tyers MB (1987) Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev 14:333–336PubMedCrossRef

137.

Taniguchi S, Hagihara K, Hamada T, Minami M, Endo T, Tsuchiyama M (2004) The inhibitory action of indisetron hydrochloride, a 5-HT3 receptor antagonist, against the anticancer drug-induced emesis in the dog, ferret and suncus. Jpn Pharmacol Ther 32:799–806

138.

Tattersall FD, Dourish CT, Duchnowski M, Swain C, Iversen SD (1990) The anti-emetic action of the novel 5-HT3 receptor antagonist L-683, 877 in the ferret. Eur J Pharmacol 183:1966–1967CrossRef

139.

Tattersall D, Newberry N, Beer MS, Rigby M, Gilbert M, Maguire JJ, Mudukotuwa N, Duchnowski M, MacKnight AT, Swain C, Kneen C, Dourish CT (1992) L-683, 877: Pharmacological Profile of a Novel 5-HT3 Receptor Antagonist. Drug Dev Res 25:17–28CrossRef

140.

Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ (2000) The novel NK1 receptor antagonist MK-0869 (L-754, 030) and its water soluble phosphoryl prodrug, L-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652–663PubMedCrossRef

141.

Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, Ladduwahetty T, Keown L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre DE, Hill RG, Hargreaves RJ (1996) Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 35:1121–1129PubMedCrossRef

142.

Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG (1993) The tachykinin NK1 receptor antagonist CP-99, 994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 250:R5–R6PubMedCrossRef

143.

The Cochrane Collaboration^® (2002) Open Learning Material

144.

Tsuchiya M, Fujiwara Y, Kanai Y, Mizutani M, Shimada K, Suga O, Ueda S, Watson JW, Nagahisa A (2002) Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11, 974) against acute and delayed cisplatin-induced emesis in the ferret. Pharmacology 66:144–152PubMedCrossRef

145.

Twissell DJ, Bountra C, Bunce KT, Dale TJ, Gardner CJ, Jordan CC, Ward P (1993) Anti-emetic properties of a non-peptide neurokinin NK1 antagonist, CP-99,994, in ferrets

146.

Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:G566–G576PubMed

147.

Watanabe Y, Okamoto M, Ishii T, Takatsuka S, Taniguchi H, Nagasaki M, Saito A (2008) Long-lasting anti-emetic effect of T-2328, a novel NK(1) antagonist. J Pharmacol Sci 107:151–158PubMedCrossRef

148.

Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, Andrews PLR (1995) The anti-emetic effects of CP-99, 994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115:84–94PubMed

149.

Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S (2006) Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets. J Pharmacol Sci 101:99–102PubMedCrossRef

150.

Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, Mutoh S (2002) Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 442:273–278PubMedCrossRef

151.

Yoshida N, Omoya H, Ito T (1992) DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog. J Pharmacol Exp Ther 260:1159–1165PubMed

152.

Yoshida N, Omoya H, Kato S, Ito T (1992) 5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. Eur J Pharmacol 216:435–440PubMedCrossRef

153.

Yoshida N, Omoya H, Kato S, Ito T (1993) Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 43:1078–1083PubMed

154.

Yoshida N, Omoya H, Une T, Ito T, kato S (1991) Pharmacological profile of the stereoisomers of AS-5370, a novel 5HT3 receptor antagonist. Jpn J Pharmacol 55(sup 1):385

155.

Yoshikawa T, Yoshida N, Hosoki K (1996) Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 301:143–149PubMedCrossRef

156.

Yoshikawa T, Yoshida N, Oka M (2001) Central antiemetic effects of AS-8112, a dopamine D2, D3, and 5-HT(3) receptor antagonist, in ferrets. Eur J Pharmacol 431:361–364PubMedCrossRef

157.

Yoshikawa T, Yoshida N, Oka M (2001) The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist. Br J Pharmacol 133:253–260PubMedCrossRef

158.

Youssefyeh RD, Campbell HF, Airey JE, Klein S, Schnapper M, Powers M, Woodward R, Rodriguez W, Golec S, Studt W et al (1992) Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides. J Med Chem 35:903–911PubMedCrossRef

159.

Youssefyeh RD, Campbell HF, Klein S, Airey JE, Darkes P, Powers M, Schnapper M, Neuenschwander K, Fitzpatrick LR, Pendley CE et al (1992) Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides. J Med Chem 35:895–903PubMedCrossRef

Title: Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists
Authors: N. Percie du Sert
J. A. Rudd
C. C. Apfel
P. L. R. Andrews
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1339-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2011

Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA)

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents

Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)

Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo

Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer